Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)
February 24 2021 - 10:26AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR
15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the
month of February 2021
Commission
File Number 001-15170
GlaxoSmithKline plc
(Translation
of registrant's name into English)
980 Great West Road, Brentford, Middlesex, TW8 9GS
(Address
of principal executive office)
Indicate
by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.
Form
20-F . . . .X. . . . Form 40-F . . . . . . . .
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(1): ____
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(7): ____
TR-1: Standard form for notification of major holdings
|
NOTIFICATION OF MAJOR HOLDINGS (to be sent
to the relevant issuer and to the FCA in Microsoft Word
format if possible)i
|
|
|
|
1a. Identity of the issuer or the underlying issuer of existing
shares to which voting rights are attachedii:
|
GlaxoSmithKline
PLC
|
|
1b. Please indicate if the issuer is a non-UK issuer
(please mark with an "X"
if appropriate)
|
|
Non-UK issuer
|
|
|
2. Reason for the notification (please mark the
appropriate box or boxes with an "X")
|
|
An
acquisition or disposal of voting rights
|
X
|
|
An
acquisition or disposal of financial instruments
|
|
|
An
event changing the breakdown of voting rights
|
|
|
Other (please specify)iii:
|
|
|
3. Details of person subject to the notification
obligationiv
|
|
Name
|
Dodge
& Cox
|
|
City
and country of registered office (if applicable)
|
San
Francisco, United States of America
|
|
4. Full name of shareholder(s) (if different from 3.)v
|
|
Name
|
|
|
City
and country of registered office (if applicable)
|
|
|
5. Date on which the threshold was crossed or
reachedvi:
|
19/02/2021
|
|
6. Date on which issuer notified
(DD/MM/YYYY):
|
22/02/2021
|
|
7. Total positions of person(s) subject to the notification
obligation
|
|
|
% of
voting rights attached to shares (total of 8. A)
|
%
of voting rights through financial instruments(total of
8.B 1 + 8.B 2)
|
Total
of both in % (8.A + 8.B)
|
Total
number of voting rights of issuervii
|
|
Resulting
situation on the date on which threshold was crossed or
reached
|
5.04%
|
|
5.04%
|
5,031,020,062
|
|
Position
of previous notification (if applicable)
|
|
|
|
|
|
8. Notified details of the resulting situation on the date on which
the threshold was crossed or reachedviii
|
|
A: Voting rights attached to shares
|
|
Class/type ofshares
ISIN
code (if possible)
|
Number of voting rightsix
|
% of voting rights
|
|
Direct
(Art 9
of Directive 2004/109/EC) (DTR5.1)
|
Indirect
(Art 10
of Directive 2004/109/EC) (DTR5.2.1)
|
Direct
(Art 9
of Directive 2004/109/EC) (DTR5.1)
|
Indirect
(Art 10
of Directive 2004/109/EC) (DTR5.2.1)
|
|
Ordinary
GB0009252882
|
|
99,377,874
|
|
1.98%
|
|
ADRs
US37733W1053
|
|
154,086,234
|
|
3.06%
|
|
|
|
|
|
|
|
SUBTOTAL 8. A
|
253,464,108
|
5.04%
|
|
|
|
B 1: Financial Instruments according to Art. 13(1)(a) of Directive
2004/109/EC (DTR5.3.1.1 (a))
|
|
Type of financial instrument
|
Expirationdatex
|
Exercise/Conversion Periodxi
|
Number of voting rights that may be acquired if the instrument
is
exercised/converted.
|
% of voting rights
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
SUBTOTAL 8. B 1
|
|
|
|
|
|
B 2: Financial Instruments with similar economic effect according
to Art. 13(1)(b) of Directive 2004/109/EC (DTR5.3.1.1
(b))
|
|
Type of financial instrument
|
Expirationdatex
|
Exercise/Conversion Period xi
|
Physical or cash settlementxii
|
Number of voting rights
|
% of voting rights
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
SUBTOTAL 8.B.2
|
|
|
|
9. Information in relation to the person subject to the
notification obligation (please mark the applicable box
with an "X")
|
|
Person
subject to the notification obligation is not controlled by any
natural person or legal entity and does not control any other
undertaking(s) holding directly or indirectly an interest in the
(underlying) issuerxiii
|
X
|
|
Full chain
of controlled undertakings through which the voting rights and/or
thefinancial instruments are effectively held starting with the
ultimate controlling natural person or legal entityxiv (please add additional rows as
necessary)
|
|
|
Namexv
|
% of voting rights if it equals or is higher than the notifiable
threshold
|
% of voting rights through financial instruments if it equals or is
higher than the notifiable threshold
|
Total of both if it equals or is higher than the notifiable
threshold
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
10. In case of proxy voting, please identify:
|
|
Name of
the proxy holder
|
|
|
The
number and % of voting rights held
|
|
|
The
date until which the voting rights will be held
|
|
|
|
|
11. Additional informationxvi
|
|
|
|
Place of completion
|
San
Francisco, USA
|
|
Date of completion
|
22/02/2021
|
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorised.
|
|
GlaxoSmithKline plc
|
|
|
(Registrant)
|
|
|
|
|
Date: February
24, 2021
|
|
|
|
|
|
|
By:/s/ VICTORIA
WHYTE
--------------------------
|
|
|
|
|
|
Victoria Whyte
|
|
|
Authorised
Signatory for and on
|
|
|
behalf
of GlaxoSmithKline plc
|
GSK (PK) (USOTC:GLAXF)
Historical Stock Chart
From May 2024 to Jun 2024
GSK (PK) (USOTC:GLAXF)
Historical Stock Chart
From Jun 2023 to Jun 2024
